Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 62

Sort by

Sort Order Select

Journal Articles

Single-day non-activated IL-18-armed CAR T cells with enhanced persistence and durable efficacy

Joseph Durgin, Shin Seo, Shadab Kazmi, Bakir Valentic, Chloe Leff, Xioling Jin, Feng Shen, Nandana Mukherjee, Ashwin Sannecy, Gabriela Plesa, Khatuna Gabunia, John Scholler, Saar Gill, Roddy O'Connor, Carl June, Saba Ghassemi

Blood (2025) 146 (Supplement 1): 4187.

https://doi.org/10.1182/blood-2025-4187

Published: 2025

Journal Articles

Age-ing study: A prospective evaluation of geriatric, patient-reported and frailty assessments to predict outcomes in older adults with acute myeloid leukemia

Catherine Lai, Thomas Greenwood, E. Paul Wileyto, Nisha Singh, Ashlena Livingston, Amanda Lopez, Selina Luger, Alexander Perl, Ximena Jordan Bruno, Elizabeth Hexner, Shannon McCurdy, Saar Gill, Gary Okano, Ali McBride, Carmelo Alonso, Keith Pratz

Blood (2025) 146 (Supplement 1): 2843.

https://doi.org/10.1182/blood-2025-2843

Published: 2025

Journal Articles

TSC-101 eliminates recipient hematopoietic cells and demonstrates potential for improved relapse-free survival in patients with AML, ALL, or MDS undergoing allogeneic HCT: Updated results from the Phase 1 (ALLOHA) trial

Monzr M. Al Malki, Yi-Bin Chen, Tania Jain, Alla Keyzner, Melhem Solh, Uday Popat, Michele Donato, Luis Pineiro, Hugo Fernandez, Saar Gill, Anson Snow, Joseph Uberti, Timothy White, Yun Wang, Cuong Nguyen, Chrystal Louis, Shrikanta Chattopadhyay, Michelle Matzko, Ran Reshef

Blood (2025) 146 (Supplement 1): 2391.

https://doi.org/10.1182/blood-2025-2391

Published: 2025

Journal Articles

CAR T cells converge on a distinct transcriptional state over time in patients with diverse hematologic malignancies

Xiaoli Mi, Dennis Yuan, Nicholas Midler, Alexander Lewis, Rebecca Murray, Alyssa Indart, Kenyon Weis, Olga Shestova, Susan DeWolf, Jae Park, Omar Abdel-Wahab, Saar Gill, Dan Avi Landau

Blood (2025) 146 (Supplement 1): 499.

https://doi.org/10.1182/blood-2025-499

Published: 2025

Journal Articles

Glucose transporter 5 enhances CAR-T cell metabolic function and serial killing

Bakir Valentic, Andre Kelly, Feng Shen, John Scholler, Max Shestov, Nathaniel Snyder, Saba Ghassemi, Nicholas Jones, Saar Gill, Roddy O'Connor

Blood (2025) 146 (Supplement 1): 2351.

https://doi.org/10.1182/blood-2025-2351

Published: 2025

Journal Articles

Cytokine-medated expansion of clonal hematopoiesis after CART therapy

Daniel Brown, Anand Bhagwat, Bryan Ciccarelli, Saar Gill

Blood (2025) 146 (Supplement 1): 3249.

https://doi.org/10.1182/blood-2025-3249

Published: 2025

Journal Articles

Lipid nanoparticle-mediated epitope editing in human HSPCs enables resistance to CD45-directed CAR-T cell therapy

Chenchen Li, Vilas Desai, Elahe Kamali Ghahe, Davin Tafuri, Rujul Jagdish Deolikar, Natalie Cooper, Nils Wellhausen, Feng Shen, Reka Geczy, Aruna Balgi, Samuel Clarke, Jennifer Moody, Anne Chew, Carl June, Saar Gill, Friederike Herbst

Blood (2025) 146 (Supplement 1): 1048.

https://doi.org/10.1182/blood-2025-1048

Published: 2025

Journal Articles

Divergent exhaustion networks define memory CD8+ T cell subset fate under chronic stimulation and reveal targets for epigenetic reprogramming

Leonel Torres, Brandon Simone, Trenton Campos, Elliot Goepfert-Waterman, Olga Shestova, Sasikanth Manne, Amy Baxter, Josephine Giles, E. John Wherry, Saar Gill

Blood (2025) 146 (Supplement 1): 4777.

https://doi.org/10.1182/blood-2025-4777

Published: 2025

Journal Articles

Cytotoxic, natural killer-like ex-tissue resident memory T-cells circulate in human chronic graft-versus-host disease at diagnosis

Patrick Mellors, Olga Shestova, Linda Perry, Nasheed Hossain, Noelle Frey, Mary Ellen Martin, Pashna Munshi, Alison Loren, Elizabeth Hexner, David Porter, Saar Gill

Blood (2025) 146 (Supplement 1): 821.

https://doi.org/10.1182/blood-2025-821

Published: 2025

Journal Articles

IL18-armored CAR T cells in relapsed/refractory B cell acute lymphoblastic leukemia

Blood (2025) 146 (Supplement 1): 812.

https://doi.org/10.1182/blood-2025-812

Published: 2025

Journal Articles

UBA1a dependency leads to synthetic lethality in vacuoles, E1-ligase, x-linked, auto-inflammatory, somatic (VEXAS) syndrome

Bryan Ciccarelli, Daniel Brown, Nathan Welty, Om Gandhi, Brandon Simone, Selina Luger, Saar Gill

Blood (2025) 146 (Supplement 1): 4944.

https://doi.org/10.1182/blood-2025-4944

Published: 2025

Journal Articles

Trials in progress: Design of a registrational Phase 2 trial (ALLOHA) using an external control arm for TSC-101 for prevention of relapse post allogeneic HCT in patients with ALL, AML, or MDS

Blood (2025) 146 (Supplement 1): 2400.

https://doi.org/10.1182/blood-2025-2400

Published: 2025

Journal Articles

CD123-directed chimeric antigen receptor T-cell (CART123) therapy for relapsed/refractory pediatric acute myeloid leukemia

Blood (2025) 146 (Supplement 1): 1643.

https://doi.org/10.1182/blood-2025-1643

Published: 2025

Journal Articles

Fried's frailty phenotype predicts survival in pts with relapsed/refractory lymphoma or myeloma undergoing chimeric antigen receptor T-cell therapy – a prospective, observational Study

Blood (2025) 146 (Supplement 1): 7189.

https://doi.org/10.1182/blood-2025-7189

Published: 2025

Journal Articles

Development of a CAR-NK therapy regulated by the KLRC1 locus as a new platform for selective control of acute myeloid leukaemia

Asunción Borrero Borrego, Sarah Sleiman, Nathan Welty, Astrid Beerlage, Almudena Navarro Bailon, Rizwan Romee, Neil Sheppard, Fermin Sanchez-Guijo, Saar Gill

Blood (2025) 146 (Supplement 1): 5907.

https://doi.org/10.1182/blood-2025-5907

Published: 2025

Journal Articles

Selection for an HIV-Resistant Immune System By Base-Edited CD45 CAR-T Cell Therapy

Nils Wellhausen, Yuqi Zhou, Michael S Bowman, Kusala Anupindi, Abhimanyu Gowda, Nils Engel, Carl H. June, Robert L. Bowman, James Riley, Saar Gill

Blood (2024) 144 (Supplement 1): 2200.

https://doi.org/10.1182/blood-2024-206371

Published: 2024

Journal Articles

Serum-Based Proteomic Analysis of Cytokine Release Syndrome in Pediatric AML Patients Receiving CART123

Saamia Farooki, Han R Fisher, Anand S Bhagwat, Tina Glisovic-Aplenc, Lusha Cao, Regina M. Myers, Haley Newman, Caroline Diorio, Saar Gill, Richard Aplenc

Blood (2024) 144 (Supplement 1): 2946.

https://doi.org/10.1182/blood-2024-201034

Published: 2024

Journal Articles

Selective Support of CAR-T Cell Therapies By Cis-Targeted IL-2 Enhances Anti-Tumor Activity and Obviates the Need for Lymphodepletion in Non-Human Primates

Blood (2024) 144 (Supplement 1): 499.

https://doi.org/10.1182/blood-2024-198249

Published: 2024

Journal Articles

Engineering Myeloid Hematopoiesis By Nonviral Chimeric Antigen Receptor Knock-in to CD33 Enhances T Cell Infiltration in the Tumor Microenvironment

Nathan E Welty, Patrick Mellors, Olga Shestova, Darryl Sams, Om Gandhi, Joelle Kim, Xinhe Shan, Saar Gill

Blood (2024) 144 (Supplement 1): 85.

https://doi.org/10.1182/blood-2024-208014

Published: 2024

Journal Articles

Comparison of CRS- and Icans-Related Outcomes for Large B Cell Lymphoma Patients Treated with Commercial Axicabtagene Ciloleucel with or without Prophylactic Dexamethasone

Alison Carulli, Hayden Elliott, Brendan Mangan, James Whittenburg, Elise A. Chong, Sunita D. Nasta, Jakub Svoboda, Stefan K. Barta, David L. Porter, Jordan S. Carter, Michael Roderick Cook, Nasheed Hossain, Saar Gill, Alfred L. Garfall, Christopher Catania, Colleen R. Kucharczuk, Stephen J. Schuster, Noelle Frey, Daniel J. Landsburg

Blood (2024) 144 (Supplement 1): 2275.

https://doi.org/10.1182/blood-2024-203726

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Single-day non-activated IL-18-armed CAR T cells with enhanced persistence and durable efficacy

Age-ing study: A prospective evaluation of geriatric, patient-reported and frailty assessments to predict outcomes in older adults with acute myeloid leukemia

TSC-101 eliminates recipient hematopoietic cells and demonstrates potential for improved relapse-free survival in patients with AML, ALL, or MDS undergoing allogeneic HCT: Updated results from the Phase 1 (ALLOHA) trial

CAR T cells converge on a distinct transcriptional state over time in patients with diverse hematologic malignancies

Glucose transporter 5 enhances CAR-T cell metabolic function and serial killing

Cytokine-medated expansion of clonal hematopoiesis after CART therapy

Lipid nanoparticle-mediated epitope editing in human HSPCs enables resistance to CD45-directed CAR-T cell therapy

Divergent exhaustion networks define memory CD8+ T cell subset fate under chronic stimulation and reveal targets for epigenetic reprogramming

Cytotoxic, natural killer-like ex-tissue resident memory T-cells circulate in human chronic graft-versus-host disease at diagnosis

IL18-armored CAR T cells in relapsed/refractory B cell acute lymphoblastic leukemia

UBA1a dependency leads to synthetic lethality in vacuoles, E1-ligase, x-linked, auto-inflammatory, somatic (VEXAS) syndrome

Trials in progress: Design of a registrational Phase 2 trial (ALLOHA) using an external control arm for TSC-101 for prevention of relapse post allogeneic HCT in patients with ALL, AML, or MDS

CD123-directed chimeric antigen receptor T-cell (CART123) therapy for relapsed/refractory pediatric acute myeloid leukemia

Fried's frailty phenotype predicts survival in pts with relapsed/refractory lymphoma or myeloma undergoing chimeric antigen receptor T-cell therapy – a prospective, observational Study

Development of a CAR-NK therapy regulated by the KLRC1 locus as a new platform for selective control of acute myeloid leukaemia

Selection for an HIV-Resistant Immune System By Base-Edited CD45 CAR-T Cell Therapy

Serum-Based Proteomic Analysis of Cytokine Release Syndrome in Pediatric AML Patients Receiving CART123

Selective Support of CAR-T Cell Therapies By Cis-Targeted IL-2 Enhances Anti-Tumor Activity and Obviates the Need for Lymphodepletion in Non-Human Primates

Engineering Myeloid Hematopoiesis By Nonviral Chimeric Antigen Receptor Knock-in to CD33 Enhances T Cell Infiltration in the Tumor Microenvironment

Comparison of CRS- and Icans-Related Outcomes for Large B Cell Lymphoma Patients Treated with Commercial Axicabtagene Ciloleucel with or without Prophylactic Dexamethasone

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only